$11.95
-0.10 (-0.83%)
Open$12.02
Previous Close$12.05
Day High$12.18
Day Low$11.56
52W High$17.15
52W Low$9.85
Volume—
Avg Volume105.6K
Market Cap417.06M
P/E Ratio—
EPS$-1.11
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+124.9% upside
Current
$11.95
$11.95
Target
$26.87
$26.87
$21.20
$26.87 avg
$38.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 792.56M | 838.23M | 726.24M |
| Net Income | 29.18M | 25.09M | 21.12M |
| Profit Margin | 3.7% | 3.0% | 2.9% |
| EBITDA | 33.32M | 33.92M | 33.30M |
| Free Cash Flow | 24.79M | 28.65M | 30.31M |
| Rev Growth | +7.9% | +14.3% | -7.3% |
| Debt/Equity | 0.15 | 0.16 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |